Evrópusambandið - íslenska - EMA (European Medicines Agency)

nabriva therapeutics ireland dac - lefamulin acetate - pneumonia, bacterial; community-acquired infections - sýklalyf fyrir almenn nota, - xenleta is indicated for the treatment of community-acquired pneumonia (cap) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of cap or when these have failed. Íhuga ætti að opinbera leiðsögn á réttri notkun af sýklalyfjum.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - lupus erythematosus, systemic - Ónæmisbælandi lyf - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - stækkun Æxli, gelding-Þola - heilsueyðandi lyf - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - ibuprofenum inn - filmuhúðuð tafla - 200 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - ibuprofenum inn - filmuhúðuð tafla - 400 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - ciprofloxacinum hýdróklóríð - tafla - 250 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - ciprofloxacinum hýdróklóríð - tafla - 500 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - Æxlishemjandi lyf - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl):following asct, orfollowing at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. systemic anaplastic large cell lymphomaadcetris in combination with cyclophosphamide, doxorubicin and prednisone (chp) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl. cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

takeda manufacturing austria ag - octocog alfa - hemophilia a - antihemorrhagics - meðferð og fyrirbyggjandi blæðingar hjá sjúklingum með dreyrasýki a (meðfæddan þáttur viii-skortur). advate inniheldur ekki von willebrand þáttur í ly árangri magni og er því ekki fram í von willebrand sjúkdómur.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloxetin - sykursýkis taugakvilla - psychoanaleptics, - meðferð við útlægum taugakvillaverkjum í sykursýki. ariclaim er ætlað í fullorðnir.